DR. DANIEL MARK STEIN M.D.
Prescription History 1841447513
Urology in Chicago, IL

NPI Status: Active since August 25, 2008

Contact Information

303 E CHICAGO AVE STE 16-703
CHICAGO, IL
ZIP 60611
Phone: (312) 503-3238

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DANIEL MARK STEIN M.D., an active Urology specialist practicing in Chicago, IL. Our medical registry currently tracks 9 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 409 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamsulosin Hcl, which accounts for 106 claims alone.


Alfuzosin Hcl Er

Generic Formulation: Alfuzosin HclSpecialty: Urology
Provider Metrics Summary
Total Claims 57
30-Day Fills 147.0
Days Supply 4,410
IL State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills110.4
Peer Average Days Supply3,278
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,530.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.86

State Avg Cost Per Claim

$28.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Alfuzosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Alfuzosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Doxazosin Mesylate

Generic Formulation: Doxazosin MesylateSpecialty: Urology
Provider Metrics Summary
Total Claims 14
30-Day Fills 20.0
Days Supply 590
IL State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills62.3
Peer Average Days Supply1,830
Conservative Utilization

This provider writes prescriptions for this formulation 48.1% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $297.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.27

State Avg Cost Per Claim

$22.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prazosin-related compound that is a selective alpha-1-adrenergic blocker.

Therapeutic Applications

Doxazosin is used alone or with other drugs to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication works by relaxing blood vessels so blood can flow more easily. Doxazosin is also used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and part of the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate frequently or urgently (including during the middle of the night). Doxazosin belongs to a class of drugs known as alpha blockers.

Dutasteride

Generic Formulation: DutasterideSpecialty: Urology
Provider Metrics Summary
Total Claims 12
30-Day Fills 36.0
Days Supply 1,080
IL State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills64.3
Peer Average Days Supply1,900
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.6% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $868.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$72.37

State Avg Cost Per Claim

$51.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.

Therapeutic Applications

This medication is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It works by reducing the size of the enlarged prostate. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate frequently or urgently (including during the middle of the night). It may also reduce the need for surgery to treat BPH. Dutasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. This medication should not be used by women or children.

Finasteride

Generic Formulation: FinasterideSpecialty: Urology
Provider Metrics Summary
Total Claims 85
30-Day Fills 235.0
Days Supply 7,026
IL State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills130.8
Peer Average Days Supply3,850
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 54.5% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,593.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.75

State Avg Cost Per Claim

$17.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.

Therapeutic Applications

Finasteride is used to shrink an enlarged prostate (benign prostatic hyperplasia or BPH) in adult men. It may be used alone or taken in combination with other medications to reduce symptoms of BPH and may also reduce the need for surgery. Finasteride may improve symptoms of BPH and provide benefits such as decreased urge to urinate, better urine flow with less straining, less of a feeling that the bladder is not completely emptied, and decreased nighttime urination. This medication works by decreasing the amount of a natural body hormone (DHT) that causes growth of the prostate. Finasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. Women and children should not use this medication.

Gemtesa

Generic Formulation: VibegronSpecialty: Urology
Provider Metrics Summary
Total Claims 15
30-Day Fills 21.0
Days Supply 630
IL State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills48.6
Peer Average Days Supply1,239
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.3% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,666.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$711.09

State Avg Cost Per Claim

$554.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat overactive bladder. Overactive bladder is a problem with how your bladder stores urine that causes a sudden urge to urinate. The urge may be hard to control, and overactive bladder symptoms may include frequent urination, strong sudden urges to urinate, or involuntary loss of urine (incontinence). Vibegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Urology
Provider Metrics Summary
Total Claims 86
30-Day Fills 133.0
Days Supply 3,954
IL State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills72.5
Peer Average Days Supply1,981
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 75.5% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $62,899.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$731.39

State Avg Cost Per Claim

$610.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Silodosin

Generic Formulation: SilodosinSpecialty: Urology
Provider Metrics Summary
Total Claims 14
30-Day Fills 40.0
Days Supply 1,200
IL State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills51.5
Peer Average Days Supply1,516
Conservative Utilization

This provider writes prescriptions for this formulation 44.0% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,061.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$218.66

State Avg Cost Per Claim

$122.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Silodosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Silodosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Urology
Provider Metrics Summary
Total Claims 106
30-Day Fills 300.1
Days Supply 9,003
IL State Average Benchmarks
Peer Average Claims85.0
Peer Average 30-Day Fills190.9
Peer Average Days Supply5,605
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,256.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.16

State Avg Cost Per Claim

$20.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Trospium Chloride Er

Generic Formulation: Trospium ChlorideSpecialty: Urology
Provider Metrics Summary
Total Claims 20
30-Day Fills 52.0
Days Supply 1,560
IL State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills49.4
Peer Average Days Supply1,427
Conservative Utilization

This provider writes prescriptions for this formulation 28.6% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,076.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$453.81

State Avg Cost Per Claim

$198.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, trospium improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. Trospium belongs to a class of drugs known as antispasmodics. It is also known as an antimuscarinic.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DANIEL MARK STEIN M.D. provides transparency into local medical care patterns within Chicago, IL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Urology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.